Autosomal recessive juvenile parkinsonism (AR-JP) is characterised by homogenous clinical features and selective degeneration of nigral neurons. Recent progress in molecular genetic analyses of AR-JP has led to the identification of a novel ubiquitin-like protein, parkin, whose precise function still remains to be elucidated. Two unrelated Japanese families had levodopa unresponsive parkinsonism complicated with cerebellar and pyramidal tract dysfunction. Genetic analysis of the parkin gene and mRNA in both families disclosed identical mutations with large deletions extending from exons 3 to 4. These results suggest that the parkin protein possesses an important function not only in the substantia nigra but also in extranigral neurons of the CNS and that the phenotype of multiple system dysfunction can also be a complication in patients with AR-JP due to variations in sites of or changes in functions by parkin mutation. (J Neurol Neurosurg Psychiatry 2001;71:231-234) 
Autosomal recessive juvenile parkinsonism (AR-JP) is characterised by several homogenous features such as early onset, typical signs of parkinsonism, and a good response to levodopa therapy. 1 2 The responsible gene for AR-JP was recently identified and designated parkin. 3 The clinical features elicited by selective degeneration in the substantia nigra and locus ceruleus 1 2 suggest that the parkin protein functions selectively in the substantia nigra compacta. However, it is also possible that the parkin protein functions not only in the substantia nigra but also in extranigral regions, because the parkin gene transcript is extensively expressed in both intranigral and extranigral regions of the brain. 3 We previously reported on two Japanese siblings with hereditary parkinsonism complicated with cerebellar and pyramidal tract dysfunction. 4 Recently, we treated another patient with similar clinical features. These three patients showed very good responses to treatment with anticholinergic drugs, but not with levodopa, 4 unlike most patients with AR-JP. We performed genetic analysis of the parkin gene in both families and identified a deletion mutation, indicating the extensive involvement of parkin protein in the extranigral nervous system. Tc-HmPAO SPECT disclosed hypoperfusion in both the striatum and cerbellar hemisphere. Parkinsonian symptoms responded very well to treatment with anticholinergic drugs but not with levodopa, indicating dysfunction of both doperminergic neurons and the striatum. The symptoms have been well controlled. Anticholinergic drugs had no beneficial eVects on their pyramidal signs or cerebellar ataxia, but these symptoms have progressed very slowly. The clinical features of the two patients from family N have been reported previously. 
Families

Materials and methods POLYMERASE CHAIN REACTION (PCR) ANALYSIS OF THE PARKIN GENE
After obtaining informed consent, genomic DNA was isolated from peripheral blood leucocytes from the patients, members of their families, and 20 control subjects. All of the 12 exons of the parkin gene were amplified individually according to the reaction conditions described by Kitada et al. 
Figure 1 (A) Genetic studies of family N and family Y. In the pedigrees (upper panel), closed squares (men) and closed circles (women) represent aVected members. The results of polymerase chain reaction (PCR) analysis (lower left of panels A and B) disclosed deletions of exons 3 and 4 in the parkin gene in aVected members (II-1 and II-2 in family N, III-1 in family Y). Southern blot analysis (lower right of panels
SOUTHERN BLOTTING ANALYSIS
Ten micrograms of genomic DNA from each of the patients and their family members were digested with EcoRI, subjected to electrophoresis, and blotted onto a nylon membrane. For preparation of a probe, human brain total RNA (Clontech, CA, USA) was reverse transcribed using a Super Script TMII RT kit (Life Technologies Inc, MD, USA) and then subjected to PCR using both the forward primer 5'-GACCATGATAGTGTTTG-3' (nt 98-114) 3 and the reverse primer 5'-GATGTTCCGA CTATTTGTTGCGATCAGGT-3', (nt 1034-1056). The amplified product was ligated into the pCR™2.1 vector (Invitrogen, CA, USA) and sequenced. Southern blotting was performed using a Gene Images CDP-Star detection module (Amersham Pharmacia Biotech, UK) and a Luminoimage analyzer LAS-1000 (Fujifilm Co, Tokyo, Japan).
REVERSE TRANSCRIPTION (RT)-PCR AND SEQUENCING ANALYSES OF THE PARKIN mRNA
Total RNA was isolated from peripheral blood leucocytes from patients II-2, III-1 and 15 control subjects as previously described. 5 One microgram of total RNA was subjected to PCR to amplify a full region of parkin cDNA using three sets of oligonucleotide primers: (1) exons 1-6: forward, 5'-GACCATGATAGTGTT-3' (nt 98-114); reverse 5'-GATGTTCCG ACTATTTGTTGCGATCAGGT-3' (nt 781-809); (2) exons 2-9: forward, 5'-CTGA GGAATGACTG GACTG-3' (nt 249-267); reverse 5'-CACTCCTCTGCACCAT ACT-3 (nt 1051-1069); and (3) exons 9-12: forward, 5'-GTACAACCGGTACC AGCA GTATG-3' (nt 1034-1056); reverse 5'-CTACACGTCG AACCAGT GGTC -3' (nt 1479-1499). The PCR reactions were repeated for 33 cycles using the following denaturation, annealing, and extension conditions: 94°C for 30 seconds, 60°C for 2 minutes, and 72°C for 3 minutes. The amplified products were cloned into the pCR™2.1 vector and sequenced using an ABI model 377 DNA sequencer (PE Biosystems, CA, USA).
Results
PCR AND SOUTHERN BLOT ANALYSES OF THE PARKIN GENE
As shown in figure 1 , PCR analysis of each of the 12 exons in the parkin gene demonstrated that all of the exons except for exons 3 and 4 were amplified in the three patients (results of exons 7 to 12 not shown for patients: II-1 and II-2 in family N and III-1 in family Y). When the parents (I-1 and I-2) and sons (III-1 and III-2) of the patients as well as the 20 control subjects were examined, all of the 12 exons were successfully amplified. In Southern blot analysis, five fragments (16 kb, 11 kb, 4.5 kb, 1.5 kb, and 0.6 kb) were detected (lane C in the lower right panels of fig 1 A) . However, the analysis of the parents' genomic DNA disclosed that a 1.5 kb fragment was not detected but one extra fragment of 4.0 kb in size was detected (lanes I-1 and I-2 in the lower right panels of fig 1 A) . These results indicate that the three patients possess identical homozygous deletion mutations in the parkin gene and that the parents in family N are heterozygous for the mutation.
RT-PCR AND SEQUENCING ANALYSES
We attempted to amplify parkin mRNA derived from peripheral blood leucocytes obtained from 15 control subjects, and we successfully obtained the expected sizes of RT-PCR products (fig 1 B; a 711 bp product for exons 1-6 , an 821 bp product for exons 2-9, and a 466 bp product for exons 9-12). The amplified products were confirmed to be parkin cDNA by sequencing analysis. When three regions encoding exons 1-6, exons 2-9, and exons 9-12 in the three patients were amplified, the sizes of RT-PCR products obtained were 348 bp, 458 bp, and 466 bp, respectively (fig 1 B) . The diVerence between the product sizes for the control subjects and patients was 363 bp in both the regions encoding exons 1-6 and 2-9. This size seems to correspond with the total length of exons 3 (241bp) and 4 (122 bp) in the control subjects. Sequencing analysis of the patients' cDNA clearly showed that the 3' end of exon 2 was connected directly to the 5' initial base of exon 5 (fig 1 C) . These results, together with the results of PCR analysis, suggest that the patients' parkin mRNA lacks both exons 3 and 4.
Discussion
In this study, we identified an abnormal parkin mRNA with a homozygous deletion mutation spanning exons 3 to 4 in three aVected patients from two unrelated families. We simultaneously detected not only mutant parkin mRNA, but also normal mRNA, the full length parkin mRNA in peripheral blood leucocytes. These findings do not agree with the results of a previous study in which only alternatively spliced parkin mRNA lacking exons 3, 4, and 5 was detected in normal peripheral leucocytes by a nested PCR method. 6 Our finding of peripheral blood leucocytes containing full length parkin mRNA would allow an easy and convenient method of finding abnormalities of the parkin gene in patients with AR-JP.
Various deletions and several point mutations in the parkin gene have been reported in patients with AR-JP, 3 7-12 and similar deletion mutations of exons 3 and 4 have also been reported. 3 7 12 However, the clinical features of the present patients, which are diVerent from previously reported clinical features, indicate dysfunctions of the corticospinal tract, cerebellum, and striatum as well as nigral dopaminergic neurons. Although the present cases indicate multiple system dysfunction, they do not fulfill the criteria of multiple system atrophy because of the presence of family history and the absence of autonomic and urinary disturbances. 13 The parkin gene transcript is extensively expressed in the brain, including the cerebral cortex, brainstem, putamen, cerebellum, and the substantia nigra, 3 and the protein has been detected in the substantia nigra, putamen, and cerebral cortex. 11 Parkin protein, localised in the Golgi complex, functions as a ubiquitinprotein ligase. 11 14 Therefore parkin gene mutation may induce accumulation of unubiquitinated substrates in neural cells, resulting in cell death.
14 However, it is not known at present whether abnormal protein ubiquitination induces neural cell death only in the nigral dopaminagic neurons. The present results suggest that the parkin protein has crucial roles in the striatum, corticospinal tract, and cerebellar system as well as in the substantia nigra, where the parkin protein and its mRNA are abundantly expressed. It is not clear why our patients with deletions in the parkin gene exhibited diVerent clinical features from those of patients with typical AR-JP. However, these clinical and genetic findings should contribute to the elucidation of the inherent functions of the parkin protein.
